Tax Policy:

Pharmaceutical Industry's Use of the Research Tax Credit

GGD-94-139: Published: May 13, 1994. Publicly Released: Jun 15, 1994.

Additional Materials:

Contact:

Office of Public Affairs
(202) 512-4800
youngc1@gao.gov

Pursuant to a congressional request, GAO reviewed the major tax benefits used by the pharmaceutical industry, focusing on: (1) the characteristics of the companies claiming research tax credits; and (2) whether Internal Revenue Service (IRS) tax administration efforts adequately ensure that pharmaceutical companies comply with tax credit legislation.

GAO found that: (1) between 1981 and 1990, the pharmaceutical industry's share of research tax credits increased by 12 percent and totalled $1.24 billion; (2) large pharmaceutical companies with assets of $250 million or more are the primary beneficiaries of research tax credits; (3) although small biotechnology companies invest more of their resources in research and development than large companies, they do not have sufficient tax liabilities to benefit from the tax credit; (4) the research tax credit is difficult for IRS to administer because auditors cannot adequately distinguish research stages, audit issues are often highly technical, and proposed regulations are confusing; and (5) although Treasury plans to clarify and finalize tax credit regulations, the regulations are not expected to distinguish between research for product innovation and research for product development.

Sep 6, 2017

May 18, 2017

May 17, 2017

Apr 27, 2017

Apr 26, 2017

Mar 8, 2017

Jan 31, 2017

Jan 27, 2017

Jan 9, 2017

Sep 13, 2016

Looking for more? Browse all our products here